Aktienanalyse zu LivaNova PLC (LIVN)LIVNLivaNova PLC

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

LivaNova PLC is a good buy right now due to its strong financial performance, indicated by a current price of $77.58 and a forward P/E ratio of 16, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company's gross margin stands at 68.09%, reflecting efficient operations and profitability. The main risk is the recent insider activity, where a director sold 1,650 shares, which could signal caution, but this represents only a 17% reduction in their holdings, maintaining a significant stake in the company.

9 analysts cover LIVN: 5 rate it Buy, 3 Hold and 1 Sell. The average price target is 72.50.